Anemia of Chronic Inflammation

Article written and reviewed by Dr Luca Moretti

Anemia of chronic inflammation is the prototype of anemia of chronic disease (see general overview). It is closely associated with persistent systemic inflammatory processes of autoimmune, infectious, rheumatologic or organ related origin, which profoundly modulate iron homeostasis and erythropoiesis. This form of anemia is not only a frequent complication but often also a negative prognostic marker in the course of chronic diseases, significantly affecting quality of life and overall outcome.

Epidemiology and clinical settings

The prevalence of anemia of chronic inflammation varies widely according to the underlying disease, its activity, the duration of inflammation and concomitant deficiencies; applying a single range to all conditions is inappropriate. The main clinical settings include:

• Rheumatologic and autoimmune diseases: rheumatoid arthritis, systemic lupus erythematosus, spondyloarthritis, systemic vasculitis, polymyalgia rheumatica.
• Chronic inflammatory bowel diseases: Crohn disease, ulcerative colitis.
• Persistent chronic infections: tuberculosis, subacute bacterial endocarditis, HIV infection, chronic osteomyelitis, chronic viral hepatitis.
• Chronic pulmonary diseases: bronchiectasis, pulmonary fibrosis, COPD with a predominant inflammatory component.
• Chronic liver diseases: liver cirrhosis, sclerosing cholangitis.
• Autoinflammatory syndromes and immunodeficiencies: when associated with persistent chronic infection or inflammation.

Advanced age, multiple comorbidities, concomitant micronutrient deficiency and the duration of the inflammatory process increase the risk of developing and perpetuating the anemic state.

Pathogenetic mechanisms and molecular pathophysiology

Anemia of chronic inflammation is a multifactorial syndrome whose pathogenesis rests on interconnected mechanisms profoundly modulated by the inflammatory cytokine environment. The key processes are:

• Dysregulation of iron homeostasis through the IL-6, hepcidin and ferroportin axis:
  Chronic immune activation induces hepatic synthesis of hepcidin mainly through IL-6; in some settings IL-1β may also contribute, whereas TNF-α acts predominantly through different mechanisms and should not be presented as a direct inducer of hepcidin. By binding to ferroportin, the only known iron exporter in enterocytes, macrophages and hepatic cells, hepcidin causes its internalization and lysosomal degradation, blocking intestinal iron absorption and the release of recycled iron from macrophages. The result is functional iron deficiency: iron is sequestered in stores but is unavailable for erythropoiesis.
• Altered erythropoietic response:
  Inflammatory cytokines suppress renal synthesis of erythropoietin (EPO) and reduce its activity on bone marrow erythroid precursors, both through direct mechanisms, including downregulation of EPO receptors, and indirect mechanisms, including oxidative stress and an altered bone marrow stromal environment.
• Direct inhibition of erythropoiesis:
  The action of TNF-α, IFN-γ and other proinflammatory molecules causes apoptosis and arrest of proliferation of erythroid progenitors (BFU-E, CFU-E), reducing the production of mature red blood cells.
• Reduced red blood cell survival:
  Chronic inflammation modifies red blood cell membranes through oxidation and altered signaling, promoting their premature removal by the reticuloendothelial system and shortening red blood cell lifespan.
• Secondary metabolic abnormalities:
  Reduced intake, hypoalbuminemia or deficiencies of vitamin B12 and folate may coexist; these deficiencies must be documented before supplementation.

Taken together, these mechanisms produce an anemia that is predominantly normocytic and normochromic, although it may become microcytic in advanced forms or when true iron deficiency is associated, with slow progression and often remaining unrecognized for a long time.

Clinical variability and phenotypic presentation

The clinical picture is highly heterogeneous and is modulated by the underlying disease, the duration of inflammation and the presence of comorbidities. Manifestations may range from subclinical forms detectable only on laboratory testing to severe anemia that worsens the symptoms of the underlying chronic disease.

Systemic symptoms: asthenia, easy fatigability, exertional dyspnea, reduced exercise tolerance, pallor of the skin and mucous membranes, less pronounced than in pure iron deficiency anemia, headache and palpitations.

Specific complications: worsening heart failure, growth delay in children, worsening cognitive deficits and nutritional status. In cases of highly active inflammation, signs of immune activation may be present, including low grade fever, sweating, arthralgia and polyarthritis.

Overlapping symptoms: the symptoms of anemia often overlap with those of the chronic inflammatory disease, making it difficult to quantify precisely the clinical impact of the anemia alone.

Diagnosis: advanced algorithms and differential diagnosis

The diagnosis of anemia of chronic inflammation is based on a logical and integrated sequence:

• Identification of the clinical context: presence of chronic inflammatory disease and suggestive clinical and historical findings.
• Typical laboratory profile:
  • Complete blood count: normocytic, normochromic anemia (MCV 80-100 fL, MCH 27-33 pg), mild to moderate (Hb rarely <8 g/dL), sometimes microcytic.
  • Ferritin: generally normal or increased; because it is an acute phase protein, it must be interpreted in the inflammatory context, and there is no universally diagnostic threshold >100 ng/mL for anemia of chronic inflammation.
  • Serum iron and transferrin saturation: reduced.
  • Total transferrin: normal or reduced.
  • Inflammatory markers: elevated ESR and CRP, sometimes with increased alpha1/2 globulins and fibrinogen.
  • Soluble transferrin receptor (sTfR): normal or mildly increased, useful in uncertain cases or when iron deficiency is also present.
  • Hepcidin: measurement is not standardized and is not routine, and can be used mainly in specialist or research settings.
• Exclusion of other causes of anemia: occult bleeding, hemolysis, vitamin deficiencies, chronic kidney disease, bone marrow neoplasms.
• Advanced differential diagnosis: when true iron deficiency and chronic inflammation coexist, combined assessment of ferritin, sTfR and inflammatory markers may support distinction between pure and mixed forms, taking into account the limitations and method dependent thresholds of sTfR.

Note: A suboptimal response to oral iron is nonspecific and may depend on adherence, dose, persistent losses, malabsorption or inflammation; by itself it does not identify isolated inflammatory anemia.

Therapeutic strategies: current principles and future perspectives

Treatment of anemia of chronic inflammation must always be individualized and multidisciplinary, with optimal control of the underlying inflammatory disease at its core.

• Etiologic treatment of the underlying disease: control of inflammatory activity with immunosuppressive drugs, including glucocorticoids, DMARDs and biologics, antibiotic or antiviral therapy for chronic infections, and management of organ complications.
• Iron treatment: oral iron may be less effective during active inflammation but is not intrinsically harmful. Intravenous iron is indicated when iron deficiency is documented and the oral route is ineffective, not tolerated or likely not absorbed; the choice of formulation depends on dose, safety and the number of infusions required.
• Erythropoietic stimulation: ESAs are not a generic treatment for inflammatory anemia; they should be used only for validated indications such as chronic kidney disease, anemia associated with noncurative chemotherapy or specific hematologic conditions.
• Correction of associated nutritional deficiencies: supplementation with vitamin B12, folate or other micronutrients only when deficiency is documented, together with nutritional optimization.
• Clinical research and future perspectives: new hepcidin inhibitors, agents that modulate iron metabolism, including anti-IL-6 and anti-hepcidin approaches, and molecular targeting strategies directed at cytokine pathways and the inflammatory response are under investigation to optimize iron availability and the effectiveness of erythropoiesis.

Transfusion of red blood cell concentrates should be considered in selected cases according to hemoglobin level, symptoms, comorbidities and the need for rapid correction, generally following a restrictive strategy; the benefit is transient and repeated transfusions carry risks, including iron overload.

Prognosis and complications

Prognosis depends on the course of the underlying disease and on the ability to achieve effective control of inflammation. Persistent inflammation and chronic anemia are associated with:

• Worsening physical performance and quality of life
• Increased risk of heart failure, especially in frail or older patients
• Possible reduction in growth and performance in children with severe chronic inflammatory disease, mainly attributable to the underlying disorder
• Increased overall morbidity and an unfavorable impact on the prognosis of the underlying disease

A multidisciplinary approach, early diagnosis and integrated management of inflammation are central to preventing the most severe complications.

Bibliography
1. Weiss G. Pathogenesis and treatment of anaemia of chronic disease. Blood Rev. 2002;16(2):87–96.
2. Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015;372(19):1832-1843.
3. Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117(17):4425–4433.
4. Fraenkel PG. Anemia of Inflammation: A Review. Med Clin North Am. 2017;101(2):285-296.
5. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011–1023.
6. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012;1823(9):1434-1443.
7. Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. Blood. 2019;133(1):40-50.
8. Cascio MJ, DeLoughery TG. Anemia: Evaluation and Diagnostic Tests. Med Clin North Am. 2017;101(2):263-284.
9. Powell DJ, Achebe MO. Anemia for the Primary Care Physician. Prim Care. 2016;43(4):527-542.
10. Fletcher A, Forbes A, Svenson N, Thomas DW; British Society for Haematology. Guideline for the laboratory diagnosis of iron deficiency in adults (excluding pregnancy) and children. Br J Haematol. 2022;196(3):523–529.